Press release
Multiple Sclerosis (MS) Therapeutics Market to Reach US$ 46.22 Billion by 2033 at 6.1% CAGR; Rising Adoption of Disease-Modifying Therapies Drives Growth - Key Players: Biogen, Novartis, Genentech
Multiple Sclerosis (MS) Therapeutics Market
The global multiple sclerosis therapeutics market reached US$ 29.09 billion in 2025 and is expected to reach US$ 46.22 billion by 2033, growing at a CAGR of 6.1% during the forecast period 2026-2033. Market growth is driven by the rising prevalence of multiple sclerosis, increasing adoption of disease-modifying treatments, and ongoing advances in oral and antibody-based therapies.
Multiple sclerosis is a chronic neurological disease in which the immune system attacks the protective covering of nerve fibers in the central nervous system. Treatment strategies vary according to disease activity, clinical presentation, and patient needs. DMTs play an important role in reducing inflammatory activity and relapses, while symptomatic treatments and rehabilitation can help patients manage the wider effects of the condition.
Key products include Ocrevus (ocrelizumab), Tysabri (natalizumab), Gilenya (fingolimod), and Kesimpta (ofatumumab). These therapies have established roles in specific MS treatment settings, although their indications, safety considerations, and suitability vary by patient. North America dominates the market, supported by established healthcare infrastructure, the presence of major pharmaceutical companies, and access to advanced therapies. Asia-Pacific is expected to record the fastest growth as diagnostic capabilities, specialist care, and access to treatment continue to expand.
Get a Free Sample PDF of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/multiple-sclerosis-therapeutics-market?sai-v
Recent Developments
September 2026 - North America/United States: Roche announced that the FDA accepted its fenebrutinib application under priority review for relapsing and primary progressive multiple sclerosis. The investigational oral BTK inhibitor demonstrated positive Phase III results, potentially expanding treatment options beyond existing disease-modifying therapies.
September 2026 - Europe/North America: Novartis reported positive Phase III REMODEL-1 and REMODEL-2 results for remibrutinib in relapsing MS. The oral BTK inhibitor reduced annualized relapse rates and MRI lesion activity compared with teriflunomide, with regulatory submissions planned.
September 2026 - Europe: The European Medicines Agency's CHMP recommended expanding Ocrevus (ocrelizumab) use to include eligible children aged 10 years and older with active relapsing forms of MS, potentially broadening access to established anti-CD20 therapy.
August 2026 - North America: Immunic reported that its Phase III ENSURE-1 and ENSURE-2 trials of vidofludimus calcium for relapsing MS remained on track for topline results by the end of 2026. The company was also preparing a Phase III program for progressive MS.
July 2026 - Europe: A Phase III head-to-head study published in The New England Journal of Medicine found rituximab noninferior to ocrelizumab for suppressing MRI-detected disease activity in newly diagnosed relapsing MS over the assessed period. The findings may influence treatment comparisons and cost-conscious prescribing, although infection rates were higher with rituximab in the trial.
Key Players
Biogen | Merck KGaA | Genentech USA, Inc. | Novartis AG | Bristol Myers Squibb Company | Genzyme Corporation (Sanofi) | Teva Pharmaceuticals USA, Inc. | TG Therapeutics, Inc. | Vanda Pharmaceuticals, Inc. | Cycle Pharmaceuticals Limited | Others
Key Highlights
Biogen - Holds a 17% share, supported by its established multiple sclerosis portfolio, including disease-modifying therapies and oral treatments.
Merck KGaA - Holds a 14% share, driven by Mavenclad and its broad expertise in multiple sclerosis treatment.
Genentech USA, Inc. - Holds a 13% share, backed by Ocrevus and its established position in relapsing and primary progressive multiple sclerosis.
Novartis AG - Holds a 12% share, supported by therapies such as Kesimpta and Mayzent for different multiple sclerosis patient populations.
Bristol Myers Squibb Company - Holds a 10% share, driven by Zeposia and its oral disease-modifying treatment portfolio.
Genzyme Corporation (Sanofi) - Holds a 9% share, supported by Aubagio and its established presence in multiple sclerosis therapeutics.
Teva Pharmaceuticals USA, Inc. - Holds a 7% share, backed by Copaxone and its portfolio of generic and specialty treatments.
TG Therapeutics, Inc. - Holds a 6% share, driven by Briumvi and its growing presence in relapsing multiple sclerosis treatment.
Vanda Pharmaceuticals, Inc. - Holds a 4% share, supported by its specialty pharmaceutical development and commercialization capabilities.
Cycle Pharmaceuticals Limited - Holds a 3% share, backed by its focus on specialized therapies for rare and complex diseases.
Others - Hold a combined 5% share, representing emerging biotechnology firms and other pharmaceutical companies developing multiple sclerosis treatments.
Buy now to access the full report: https://www.datamintelligence.com/buy-now-page?report=multiple-sclerosis-therapeutics-market?sai-v
Market Drivers
Rising Multiple Sclerosis Prevalence: Increasing diagnosis of MS drives demand for effective disease management.
Advancements in Disease-Modifying Therapies: New treatments help reduce relapses and slow disease progression.
Growing Awareness and Early Diagnosis: Improved diagnostic methods support timely treatment initiation.
Increasing Research Investment: Pharmaceutical investment accelerates the development of innovative MS therapies.
Expansion of Personalized Treatment: Biomarker research and individualized care support improved treatment selection.
Industry Developments
Development of Novel Disease-Modifying Therapies: Research is advancing treatments designed to control disease activity.
Expansion of Monoclonal Antibodies: Biologic therapies are broadening options for patients with active MS.
Advancements in Oral Treatments: Oral disease-modifying drugs offer convenient alternatives to injectable therapies.
Research into Remyelination Therapies: Studies are exploring treatments that may support nerve repair.
Growth of Combination and Sequential Treatment Research: Clinical studies are evaluating strategies to improve long-term disease control.
Increasing Clinical Trial Activity: Research is assessing new therapies for relapsing and progressive forms of MS.
Regional Insights
North America: Holds a 40% share, driven by advanced neurological care and strong pharmaceutical research.
Europe: Holds a 29% share, supported by established MS treatment centers and access to disease-modifying therapies.
Asia-Pacific: Holds a 22% share, driven by improving diagnostic capabilities and expanding neurological services.
Latin America: Holds a 5% share, supported by gradual improvements in diagnosis and treatment access.
Middle East & Africa: Holds a 4% share, driven by expanding specialist care and growing awareness of neurological disorders.
Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/multiple-sclerosis-therapeutics-market?sai-v
Key Segments
➥ By Disease Type
Relapsing-Remitting MS: Covers MS characterized by relapses followed by periods of recovery.
Secondary-Progressive MS: Includes MS that gradually worsens after an initial relapsing-remitting phase.
Primary-Progressive MS: Covers MS characterized by steady disease progression from onset.
Clinically Isolated Syndrome: Includes the first episode of neurological symptoms suggestive of MS.
➥ By Drug Class
Disease-Modifying Therapies: Slows disease progression and reduces relapse frequency.
Corticosteroids: Helps manage acute MS relapses by reducing inflammation.
Monoclonal Antibodies: Targets specific immune mechanisms involved in MS.
Others: Includes additional medications used to manage MS symptoms and complications.
➥ By Route of Administration
Oral: Includes MS medications taken by mouth.
Injectable: Covers medications administered through injections or infusions.
➥ By Distribution Channel
Hospital Pharmacies: Supplies MS therapies through hospital pharmacies.
Retail Pharmacies: Provides prescribed MS medications through retail outlets.
Online Pharmacies: Distributes MS medications through online pharmacy platforms.
Explore Other Related Reports Here: https://www.innovations-i.com/mypage/release/?id=2669103
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Multiple Sclerosis (MS) Therapeutics Market to Reach US$ 46.22 Billion by 2033 at 6.1% CAGR; Rising Adoption of Disease-Modifying Therapies Drives Growth - Key Players: Biogen, Novartis, Genentech here
News-ID: 4662230 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Electric Vehicles Battery Recycling Market Gains Momentum as Redwood Materials C …
Market Size and Growth 2026
Redwood Materials closed a US$425 million Series E funding round in January 2026 to accelerate its energy storage platform while strengthening its integrated battery recycling and critical minerals business. The investment supports a business model that connects end-of-life battery collection, material recovery, refining, and second-life energy storage. This approach is commercially relevant to the electric vehicles battery recycling market because it creates additional value from used…
Chronic Lymphocytic Leukemia (CLL) Therapeutics Market to Reach US$ 10.27 Billio …
The global chronic lymphocytic leukemia (CLL) therapeutics market is expanding as treatment strategies increasingly shift toward targeted medicines, combination regimens, and therapies designed to improve long-term disease management. Growing investment in hematological cancer research, continued development of novel drug candidates, and the availability of oral treatment options are reshaping the competitive landscape. Pharmaceutical companies are focusing on therapies that can improve disease control, delay progression, and address the needs of…
Automatic Low Voltage Disconnect Switches Market Gains Momentum as ABB Reports U …
The automatic low voltage disconnect switches market is benefiting from advances in electrical protection and energy-efficient power distribution. On November 5, 2025, ABB launched its next-generation OT Plus switch-disconnector range, covering 16-160 A and offering up to 53% lower power losses. Designed for power distribution boards, control panels, industrial automation, and critical infrastructure, the product strengthens demand for efficient switching technologies. Although switch-disconnectors serve different functions from automatic low-voltage disconnect…
More Than Two-Thirds of Organizations Lose US$300,000 per Hour During Major IT I …
Major IT incidents are becoming a financial and operational risk that enterprises cannot manage efficiently through manual monitoring alone. More than two-thirds of organizations surveyed in PagerDuty's 2026 State of AI-First Operations report said major incidents cost them over US$300,000 per hour, while 34% reported losses of at least US$500,000 per hour. These figures highlight the commercial importance of AI-powered IT operations platforms that correlate alerts, detect anomalies, identify root…
More Releases for Hold
Global Legal Hold Software Market Size by Application, Type, and Geography: Fore …
According to Market Research Intellect, the global Legal Hold Software market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The Legal Hold Software market is steadily expanding as organizations face increasing legal and regulatory scrutiny. This…
Twitch takes hold of the US Game Streaming Market can it hold its dominance? : K …
From the year 2011, when the game streaming platforms comes to a rise, Twitch was already a budding application, which started off slow but spread its wings in 2014, with celebrities coming to make a proper environment for budding players. By 2022, Twitch had almost 9 Million streamers, among which nearly everyone had a minimum 25 Million viewers, stating a 5% month-on-month (MOM) growth.
STORY OUTLINE
• Twitch TV has a greater number…
Developing Markets Hold Immense Potential for Telemedicine
Telemedicine and its applications have been growing rapidly, with technological advancements fuelling the sector’s growth. According to a new research report by RNCOS, the developing markets, such as India and China are largely underpenetrated for telemedicine, and hence, represent a major opportunity area. The telecommunications network and technologies are growing at an unprecedented rate in these economies, where the demographic profiles are large, and non-uniform healthcare facilities are available.…
Oswego BOA To Hold Public Meeting
Oswego, NY, September 20, 2011 – The Oswego Brownfield Opportunity Area (BOA) Steering Committee invites residents, business owners, property owners and others who have an interest in redevelopment of the waterfront, downtown and nearby industrial areas to a public meeting on Tuesday, September 27, 2011 at 7:00 p.m. at the Econo Lodge, 70 E. 1st Street. Meeting attendees will discuss options for redevelopment of key sites and areas within the…
SF SPCA to Hold Art Show Benefit
The San Francisco SPCA is pleased to announce its first art exhibition/benefit at the Leanne B. Roberts Animal Care Center Gallery, entitled “Characters, Friends and Neighbors.” This new endeavor will get art on the walls of the beautiful facility, feature a diverse group of local artists, and most importantly support the SF SPCA’s mission. 25% of all art sales from the exhibitions will go directly to the SF SPCA.
For…
Innermost Secrets Hold Educational Symposium
Cardiff, United Kingdom (12 November 2010) - Innermost Secrets, a leading fertility clinic, provide an educational symposium for patients and medical professionals.
Cardiff-based private fertility clinic, Innermost Secrets, was the first in the UK to launch a service for pregnant women at risk of premature birth and late miscarriage earlier in 2010. In 2011 they will be raising awareness of being ‘Born Too Soon’ with an educational symposium for patients and…
